Clinical Trials
67 trialsLapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
National Cancer Institute (NCI)
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
National Cancer Institute (NCI)
Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Stereotactic Radiosurgery in Treating Patients With Brain Tumors
National Institutes of Health Clinical Center (CC)
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
National Cancer Institute (NCI)
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
National Cancer Institute (NCI)
Natural History of Patients With Brain and Spinal Cord Tumors
National Institutes of Health Clinical Center (CC)
AZD8055 for Adults With Recurrent Gliomas
National Institutes of Health Clinical Center (CC)
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
National Cancer Institute (NCI)
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
National Cancer Institute (NCI)
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
National Cancer Institute (NCI)
FR901228 in Treating Patients With Recurrent High-Grade Gliomas
National Cancer Institute (NCI)
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
National Institutes of Health Clinical Center (CC)
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
National Cancer Institute (NCI)
Sunitinib in Treating Patients With Recurrent Malignant Gliomas
National Cancer Institute (NCI)
Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
National Institutes of Health Clinical Center (CC)
VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide
National Cancer Institute (NCI)
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
National Cancer Institute (NCI)
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
National Cancer Institute (NCI)
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
CC-5013 in Treating Patients With Recurrent Glioma
National Cancer Institute (NCI)
CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas
National Cancer Institute (NCI)
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
National Cancer Institute (NCI)
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
National Cancer Institute (NCI)
Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma
National Cancer Institute (NCI)
Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma
National Cancer Institute (NCI)
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
National Cancer Institute (NCI)
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
National Cancer Institute (NCI)
Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma
National Cancer Institute (NCI)
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
National Cancer Institute (NCI)
Cilengitide in Treating Children With Refractory Primary Brain Tumors
National Cancer Institute (NCI)
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
National Cancer Institute (NCI)
Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma
National Cancer Institute (NCI)
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
National Cancer Institute (NCI)
Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma
National Cancer Institute (NCI)
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
National Cancer Institute (NCI)
Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors
National Cancer Institute (NCI)
Pharmacologic Study of Methotrexate in Patients Undergoing Stereotactic Biopsy for Recurrent High-Grade Glioma
National Cancer Institute (NCI)
Suramin in Treating Patients With Recurrent Primary Brain Tumors
National Cancer Institute (NCI)
Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors
National Cancer Institute (NCI)
Procarbazine in Treating Patients With Recurrent Brain Tumor
National Cancer Institute (NCI)
COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors
National Cancer Institute (NCI)
Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma
National Cancer Institute (NCI)
Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma
National Cancer Institute (NCI)
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
National Cancer Institute (NCI)
Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma
National Cancer Institute (NCI)
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
National Cancer Institute (NCI)